Vertex announces results from phase 2 study of suzetrigine for the treatment of painful lumbosacral radiculopathy

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced results from its phase 2 study of suzetrigine, an investigational, oral, highly selective nav1.8 pain signal inhibitor in people with painful lumbosacral radiculopathy (lsr). the study met its primary endpoint with statistically significant and clinically meaningful reduction in pain on the numeric pain rating scale (nprs). efficacy results the study's primary endpoint was a within-group change from base.
VRTX Ratings Summary
VRTX Quant Ranking